When the golden-hour evacuation plan fails — the aircraft can't fly, the route isn't secure, the nearest surgical facility is hours away — a medic is left managing a critically injured casualty with whatever is in reach. Prolonged Field Care (PFC) is the discipline built for that gap. Recent years have made real capability deliverable in that setting: room-temperature-stable blood products, remote specialist consultation, monitoring adjuncts that don't need a scanner. What's largely missing is direct proof that any of it changes whether a casualty survives.

The Gap Prolonged Field Care Exists to Close

PFC assumes evacuation will not go to plan. One narrative review cites that only about 2% of forward casualties received blood products before reaching a surgical facility — a descriptive figure about access, not a treatment-efficacy claim, but a useful illustration of how far forward the resuscitation problem actually starts. PFC bundles six practice areas into one discipline aimed at buying time safely: stopping bleeding, banking and giving blood, watching for brain injury without imaging, managing pain and sedation, controlling infection, and getting expert advice remotely.

Across those six domains, this review graded 37 claims drawn from 29 studies: zero reached High strength, two reached Moderate, sixteen Low, and nineteen Very Low. No paper in the corpus tested prolonged field care itself against a comparator — the effect of evacuation delay on survival is, at present, essentially unmeasured. That single fact should sit alongside every capability described below.

What follows is not a case against PFC. It's a case for reading the evidence at the strength it actually has — because operational readers are better served by an honest map of what's solid and what's still doctrine-only than by false confidence in either direction.

Capability Claims vs. Outcome Claims: The Idea That Organizes Everything Below

Most of what this evidence base supports is a capability claim — that a given tool, product, or technique can be delivered in austere, delayed-evacuation conditions. Far fewer findings rise to an outcome claim — that the same tool improves survival or reduces morbidity. Collapsing the two, letting "this is fieldable" imply "this saves lives," is the single most common inflation risk in PFC communication, and it's worth naming explicitly every time a new tool is discussed.

The corpus's only two Moderate-strength findings illustrate the point well. Both come from a single RCT of ketamine versus morphine for prehospital analgesia — and that trial excluded the population its own guidance domain is named for (TBI and intracranial hypertension). Even the strongest evidence in this review carries a built-in generalisation gap.

Where Doctrine and Evidence Diverge

What Six Domains of Evidence Actually Show

Weighing capability against outcome domain by domain gives a more useful picture than any single headline number. The pattern below repeats: real, gradeable evidence for deliverability; almost none for downstream patient benefit.

What This Means for Decisions Made Under Delay

PFC genuinely gives a medic a fuller toolkit than a decade ago, and several of those tools carry real, if modest, evidence for deliverability in austere conditions. That's not a small thing operationally — logistics and feasibility are the practical bottleneck in delayed evacuation, and closing that gap has value on its own terms.

What the evidence does not yet support is treating any single tool, or PFC as a bundle, as a validated outcome-changer. Guideline adoption is not evidence of clinical effect, and several of the strongest-sounding numbers here come from settings that don't match the operational one: healthy volunteers, civilian trauma registries, and animal or mechanical-lung testing are routinely extrapolated to military casualties under extended delay. Funding and conflict-of-interest disclosure is also largely absent across this corpus, including all five blood-product studies reviewed, and one confirmed non-independent funding relationship exists behind the REBOA rollout report.

The field's single biggest open question is also its defining operational variable: no study in this evidence base measures patient outcome as a function of how long evacuation was actually delayed. Closing that gap — not adding another device or protocol — is where the next real advance in PFC evidence needs to happen.

Key Statistics at a Glance

What the Research Doesn’t Yet Tell Us

No paper in this corpus tests prolonged field care itself against a comparator — the effect of evacuation delay on survival remains essentially unmeasured, and that stands above every other caveat here. The corpus's strongest evidence also excludes its own target population: both Moderate-strength findings come from a trial that excluded TBI and intracranial hypertension casualties. Most other findings stop at a surrogate endpoint — occlusion rate, a coagulation marker, diagnostic accuracy, consult volume, cost avoidance — rather than a patient-important outcome; four source papers say so explicitly in their own text.

Population mismatch runs through nearly the entire evidence base. Healthy volunteers, lower-severity civilian trauma, a civilian registry, veterinary and animal studies, and mechanical-lung or cadaver testing are all, at some point, extrapolated toward military casualties under extended delay. Two domains — sepsis/wound management and CPG evolution/training — currently have zero measured outcome data of any kind; that should be read as an absence of evidence, not a weak positive finding.